AUS
NZ
UK
CA
USA
IND
Headlines
- Merck’s Q2 results exceeded revenue and earnings estimates.
- Keytruda sales drove growth, but Gardasil faced shipment issues.
- Stock is trading near estimated value, with an uncertain future outlook.
Merck (NYSE:MRK) recently reported its Q2 results, surpassing expectations with $16.1 billion in revenue and adjusted earnings of $2.28 per share, beating estimates of $15.9 billion and $2.20, respectively. This growth was mainly fueled by the strong performance of Keytruda. Despite this positive outcome, the company revised its full-year earnings forecast downward, leading to a 10% drop in its stock price post-announcement. Although Merck demonstrated a robust Q2, its current stock price of around $115 suggests it is fully valued.
Merck’s Recent Stock Performance
Merck's stock has climbed approximately 45% from $80 in early January 2021 to around $130 now, mirroring the S&P 500's returns over the same period. However, Merck hasn't consistently outperformed the market, with returns of 2% in 2021, 49% in 2022, and 1% in 2023. In comparison, the S&P 500 yielded 27% in 2021, -19% in 2022, and 24% in 2023, indicating that Merck underperformed the index in 2021 and 2023.
Sector Challenges and Portfolio Insights
Consistently outperforming the S&P 500 has been a challenge for individual stocks in recent years, including major players in the Health Care sector like UNH and JNJ, as well as tech giants like GOOG, TSLA, and MSFT. Conversely, the Trefis High Quality (HQ) Portfolio, consisting of 30 stocks, has outperformed the S&P 500 annually, offering better returns with less volatility compared to the benchmark index.
Current Economic Environment and Valuation
Given the current economic uncertainty with high oil prices and elevated interest rates, Merck might face similar challenges as in 2021 and 2023, potentially underperforming the S&P 500 over the next year. From a valuation standpoint, Merck’s stock appears appropriately priced. Merck’s valuation is estimated at $120 per share, close to its current market price of $115. Currently, the stock trades at 4.9x trailing revenues, compared to a five-year average P/S ratio of 4.5x.
Q2 Performance Highlights
Merck’s Q2 revenue increased by 7% year-over-year, driven by Keytruda’s 16% rise in sales to $7.3 billion. However, Gardasil sales grew only 1% to $2.5 billion due to shipment issues in China. The company’s adjusted gross margin improved by 430 basis points to 80.9%, thanks to a favorable product mix. Higher revenues and expanded margins resulted in an adjusted bottom line of $2.28 per share, compared to a loss per share of $2.06 in the prior-year quarter.
Future Prospects
Looking ahead, Merck is expected to continue benefiting from Keytruda’s label expansion, and the shipment issue with Gardasil is likely to be temporary, with sales growth anticipated to improve in the coming quarters. Additionally, recent acquisitions, including Prometheus, Acceleron, Imago, Harpoon Therapeutics, and EyeBio, are expected to boost Merck’s top and bottom-line growth in the coming years. However, Merck lowered its full-year 2024 earnings outlook to $7.95-$8.04 per share from the previous estimate of $8.53-$8.65 per share, primarily due to one-time charges related to the acquisitions of Harpoon Therapeutics and EyeBio.
Overall, while Merck’s Q2 results were strong, the lower sales growth for Gardasil and the downward revision of the earnings forecast were slight disappointments. From a valuation perspective, Merck’s stock appears fully priced at around $115. For a comparative analysis, exploring how Merck’s peers perform on critical metrics can provide additional insights into its market positioning.
